Edwards Lifesciences Corporation (EW) Stock Grade

About Edwards Lifesciences Corporation's fundamentals

Edwards Lifesciences is a $49.9 billion medical device company with solid revenue growth of 11.6% year-over-year and a healthy net margin of 17.7%, indicating efficient conversion of sales into profit. However, the company trades at a P/E ratio of 46.4, which is substantially elevated relative to broader market averages, reflecting significant price paid per dollar of earnings. The return on equity of 10.4% is modest, suggesting moderate efficiency in generating returns from shareholder capital. The company does not currently pay a dividend, meaning returns depend entirely on capital appreciation.